Nanochon
A 3D-printed synthetic cartilage implant designed to replace damaged knee tissue and stimulate the growth of natural bone and cartilage.
- CEO / Founder
- Benjamin Holmes
- Team Size
- 11-50
- Stage
- Clinical-stage; recently secured Series A/Seed extension funding to initiate first-in-human clinical trials under FDA and Health Canada pathways.
- Total Funding
- $12.2M
- Latest Round
- Series A Extension
- Key Investors
- ["Cultivate(MD) Capital Funds","UVA Licensing & Ventures Group (LVG) Seed Fund","Alumni Ventures","Ben Franklin Technology Partners","Tysons Wealth Advisors"]
Technology & Products
Key Products
["ChondroCore (Flagship 3D-printed synthetic cartilage scaffold)","Proprietary Nanocomposite Resins (for orthopedic additive manufacturing)","Patient-specific implant mapping and design services"]
Technological Advantage
Utilizes a proprietary polyurethane and ceramic nanocomposite material that is 3D-printable, load-bearing, and mechanically matched to human cartilage, providing a faster and more cost-effective solution than lab-grown cell therapies.
Market & Competition
Target Customers
Orthopedic surgeons, sports medicine specialists, and patients suffering from focal cartilage lesions or early-stage osteoarthritis.
Industry Verticals
["Medical Devices","Orthopedics","Regenerative Medicine","Additive Manufacturing (3D Printing)"]
Competitors
["Vericel (MACI)","CartiHeal (acquired by Smith & Nephew)","Episurf Medical"]